连花清瘟胶囊和α-干扰素联合洛匹那韦/利托那韦治疗新型冠状病毒肺炎30例

汪升早; 王华军; 陈鸿明; 岳玉; 卜凡进; 张雪梅

doi:10.13898/j.cnki.issn.1000-2200.2020.02.004

连花清瘟胶囊和α-干扰素联合洛匹那韦/利托那韦治疗新型冠状病毒肺炎30例

Lianhua Qingwen capsule and interferon-α combined with lopinavir/ritonavir for the treatment of 30 COVID-19 patients

摘要

摘要:
目的观察洛匹那韦/利托那韦治疗新型冠状病毒肺炎的疗效。
方法将新型冠状病毒肺炎60例病人分为2组，各30例，对照组应用连花清瘟胶囊和α-干扰素治疗，观察组在对照组基础上联用洛匹那韦利/托那韦治疗，比较2组治疗效果。
结果观察组显著有效13例，部分有效10例；对照组显著有效3例，部分有效11例；观察组病人的治疗有效率为76.67%，明显高于对照组的46.67%（P < 0.01）。
结论洛匹那韦/利托那韦治疗新型冠状病毒肺炎有效。

Abstract:
ObjectiveTo investigate the efficacy of lopinavir/ritonavir for the treatment of corona virus disease 2019 (COVID-19).
MethodsA total of 60 patients with COVID-19 were divided into two groups (30 cases in each group).The control group was treated with Lianhua Qingwen capsule and interferon-α, and the observation group was treated with lopinavir/ritonavir on the basis of control group.The therapeutic efficacy of two groups was compared.
ResultsIn observation group, 13 cases were with notable therapeutic efficacy, and 10 cases with partially effective efficacy; in control group, 3 cases were with notable therapeutic efficacy, and 11 cases with partially effective efficacy.The effective rate of treatment in observation group (76.67%) was significantly higher than that in control group (46.67%) (P < 0.01).
ConclusionsLopinavir/ritonavir is effective for the treatment of COVID-19.

HTML全文

参考文献(6)

施引文献

资源附件(0)